The investment process at most venture capital firms is opaque to founders approaching them for the first time. What actually happens to a pitch deck after it is submitted? Who reads it, and what are they looking for? What does the diligence process involve, and what makes it move faster or slower? What are the real reasons a firm passes on a company that looks compelling on paper?

At Root Evidence Ventures, we believe that transparency about our investment process is good for everyone. It helps founders prepare more effectively for investor conversations, reduces wasted time on meetings that are not a fit, and ultimately produces better investment relationships when a deal does happen because the expectations on both sides are aligned from the start.

This piece is a detailed account of how we evaluate consumer and health companies at the seed stage. It is not a fundraising guide — there are many of those, and we are not trying to add to that genre. It is an honest description of what we look for, how we think, and what influences our decisions, for better or worse.

Stage One: Initial Review and Category Fit

Every pitch that reaches us goes through an initial review by a member of the Root Evidence team within two weeks of submission. This initial review has one primary question: is this company in a category and at a stage where we can add genuine value? We are a seed-stage consumer and health focused fund. We do not invest in enterprise software, in marketplace businesses, in real estate, or in categories outside our focus area. We do not lead rounds at the growth stage. We do not invest in companies that are already at scale and need capital primarily for operational expansion.

The initial review also includes a quick assessment of the founding team's LinkedIn profile and any available information about the company's early traction. At the seed stage, we are less focused on traction metrics than on founder profile, but preliminary signals about team quality and category expertise inform whether we prioritize the meeting.

Founders who pass the initial category fit assessment receive a response within two to three weeks of submission. Founders who do not fit our focus area receive a decline within the same window with a brief explanation of why. We try to be respectful of founders' time and to provide enough context for the decline to be useful rather than just a form email.

Stage Two: The Exploratory Meeting

The first investor meeting at Root Evidence Ventures is an exploratory conversation, not a pitch evaluation. We come to this meeting having done enough background research to have genuine questions rather than just letting the founder present. We want to understand the founder's relationship with the problem they are solving, the research process that led them to their current product and go-to-market thesis, and the specific customer insight that underpins their differentiation strategy.

We ask a specific set of questions in every exploratory meeting. Who is your customer, and how do you know? What does your customer currently use to solve the problem your product addresses? What happened the first time you talked to a customer who had used your product for thirty days? What surprised you most in your first fifty customer conversations? These questions are designed to surface the quality of a founder's customer insight quickly, because that insight is the primary signal we are evaluating at this stage.

We also ask founders to describe their honest view of what is missing in the current product or go-to-market approach and what they would do differently if they were starting from scratch. Founders who can answer this question with genuine self-awareness tend to be founders who will identify problems early and address them deliberately rather than letting them compound. This self-awareness is as important to us as the quality of the answers to the other questions.

Stage Three: Deep Diligence

When we decide to move a company into active diligence, we share a diligence request list that covers five areas: team background and reference checks, market analysis and competitive landscape, product and technology, financial model and unit economics, and go-to-market and customer acquisition. The depth of each area varies based on the company's stage and the specific questions that emerged in the exploratory meeting.

The team diligence is typically the most intensive part of our process for seed-stage investments. We conduct reference checks with former colleagues, prior employers, and where possible, early customers or investors in prior companies. We are looking for signals about how a founder operates under pressure, how they treat the people they work with, and whether the story they have told us about their background matches the experience of people who have worked alongside them. We have passed on investments where the product and market were compelling because the reference checks revealed something about founder character or operating style that we did not think we could work with over a multi-year investment horizon.

The unit economics diligence at seed stage is less about validating existing numbers — which are often too early-stage to be meaningful — and more about evaluating whether the founder has a sophisticated and realistic model of the economics they are trying to build. We ask founders to walk us through their assumptions about customer acquisition cost, retention rate, and contribution margin at scale. The assumptions themselves are less important than the quality of the reasoning behind them and the founder's ability to articulate what they would need to prove to achieve those assumptions.

Stage Four: The Partner Meeting and Investment Committee

Companies that complete the diligence process meet with the full Root Evidence Ventures investment team in a partner meeting. This meeting is the last opportunity for any member of the team to raise concerns, share enthusiasm, or ask questions that have not been addressed in prior conversations. We aim to complete the partner meeting within two to three weeks of completing diligence.

Our investment committee process is designed to reach a yes or no within one week of the partner meeting. We do not do extended decision-making processes for seed investments — both because it is unfair to founders who have other options and because we have found that extended deliberation at the seed stage usually reflects a question about fundamental fit that additional diligence will not resolve. If we are genuinely excited about a company and a founder, we move quickly. If we are not genuinely excited, a few more weeks of deliberation typically does not change that.

What We Pass On and Why

Being transparent about why we pass is as important as describing what we invest in. The most common reason we pass at the seed stage is a gap between a founder's articulation of customer insight and the primary research that would support that insight. When a founder describes their customer with a level of generality that suggests they have built a market thesis from secondary research rather than primary conversations, we struggle to have confidence in the product's ability to achieve the outcome-based retention that we believe is necessary for a health or DTC brand to be defensible over time.

The second most common reason is unit economics that do not have a credible path to venture-scale margins, even with scale. Some consumer and health businesses are great businesses at the scale they can naturally reach but cannot generate the returns that a venture capital fund requires because their category margins are structurally limited. We try to identify these situations early in the process so we are not wasting a founder's time with an extended diligence process that leads to a structural rejection.

We also pass on companies where the team composition creates specific gaps that we cannot see a path to filling. Consumer and health require both brand sensibility and either operational depth or scientific credibility, depending on the category. Teams that have one without the other and do not have a specific plan for adding the missing dimension often struggle with predictable execution challenges that make the risk-return proposition unfavorable at the seed stage.

Key Takeaways

  • Initial review at Root Evidence Ventures focuses on category fit and stage alignment. Founders who are clearly outside our focus area receive a response within two to three weeks.
  • The exploratory meeting is designed to surface the quality of a founder's customer insight through specific questions about primary research and customer conversations.
  • Team diligence is the most intensive part of the process at seed stage because founder quality is the primary investment thesis when other variables are early.
  • We pass most frequently on companies where customer insight is insufficiently primary-research-driven, where unit economics have no credible path to venture-scale margins, or where team composition has unaddressed structural gaps.
  • Our investment committee process is designed to reach a yes or no within one week of the partner meeting. We do not use extended deliberation as a way of keeping options open.

Conclusion

Transparency about the investment process serves everyone in the venture ecosystem better than opacity. Founders who understand how we evaluate companies can prepare more effectively for our conversations and can make more informed decisions about whether Root Evidence Ventures is the right partner for their specific company at their specific stage. We hope this account is useful, and we welcome questions about the process from any founder who is considering approaching us.

To start a conversation, reach us through our contact page. We respond to every inquiry from founders working in consumer DTC and health, regardless of stage, because the best investor relationships often begin with conversations that are too early for a formal investment process.